Datopotamab deruxtecan for injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Daiichi Sankyo Europe GmbH
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- Treatment of adults with unresectable or metastatic HR-positive, HER2-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-negative) who have received endocrine therapy and at least one line of chemotherapy for advanced disease.
- Indication source and scope
- Source date(s): 2025, 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
- Prescribing-information limitations
- Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
Open the interactive record, public price references and discussions